Neuroinflammation as a therapeutic target in neurodegenerative diseases

Disease-Modifying Targets in Neurodegenerative Disorders: Paving the Way for Disease-Modifying Therapies

Volumn , Issue , 2017, Pages 49-80

  Gordon, Richard ^a   Woodruff, Trent M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antiinflammatory therapeutics; Neurodegeneration; Neuroinflammation; Parkinsons disease; Pharmacological inhibitors; Therapeutic targets

Indexed keywords

EID: 85032702141     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-805120-7.00003-8     Document Type: Chapter

References (229)

1. Ward R.J., et al. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014, 13(10):1045-1060.
2. Joining forces to fight neurodegenerative diseases. Lancet Neurol. 2013, 12(2):119. The Lancet.
3. Prince M., et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013, 9(1):63-75.
4. Obeso J.A., et al. Missing pieces in the Parkinsons disease puzzle. Nat. Med. 2010, 16(6):653-661.
5. Heneka M.T., Kummer M.P., Latz E. Innate immune activation in neurodegenerative disease. Nat. Rev. Immunol. 2014, 14(7):463-477.
6. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinsons disease. Trends Neurosci. 2007, 30(5):244-250.
7. Zhu X., et al. Alzheimers disease: the two-hit hypothesis. Lancet Neurol. 2004, 3(4):219-226.
8. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci. 2007, 8(1):57-69.
9. Lin M.T., Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795.
10. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci. 2003, 4(1):49-60.
11. Eisele Y.S., et al. Targeting protein aggregation for the treatment of degenerative diseases. Nat. Rev. Drug Discov. 2015, 14(11):759-780.
12. Peelaerts W., et al. Alpha-synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015, 522(7556):340-344.
13. Luk K.C., et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 2012, 209(5):975-986.
14. Luk K.C., et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338(6109):949-953.
15. Polymenidou M., Cleveland D.W. Prion-like spread of protein aggregates in neurodegeneration. J. Exp. Med. 2012, 209(5):889-893.
16. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 2005, 18(3):315-321.
17. Liu B., Gao H.M., Hong J.S. Parkinsons disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ. Health Perspect. 2003, 111(8):1065-1073.
18. Crotti A., Glass C.K. The choreography of neuroinflammation in Huntingtons disease. Trends Immunol. 2015, 36(6):364-373.
19. Glass C.K., et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140(6):918-934.
20. Barres B.A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008, 60(3):430-440.
21. Azevedo F.A., et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J. Comp. Neurol. 2009, 513(5):532-541.
22. Herculano-Houzel S. The remarkable, yet not extraordinary, human brain as a scaled-up primate brain and its associated cost. Proc. Natl. Acad. Sci. USA 2012, 109(Suppl. 1):10661-10668.
23. Saijo K., Glass C.K. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol. 2011, 11(11):775-787.
24. Nayak D., Roth T.L., McGavern D.B. Microglia development and function. Annu. Rev. Immunol. 2014, 32:367-402.
25. Schafer D.P., Stevens B. Microglia function in central nervous system development and plasticity. Cold Spring Harb. Perspect. Biol. 2015, 7(10):pa020545.
26. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308(5726):1314-1318.
27. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10(11):1387-1394.
28. Davalos D., et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005, 8(6):752-758.
29. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996, 19(8):312-318.
30. Napoli I., Neumann H. Protective effects of microglia in multiple sclerosis. Exp. Neurol. 2010, 225(1):24-28.
31. Simard A.R., Rivest S. Neuroprotective effects of resident microglia following acute brain injury. J. Comp. Neurol. 2007, 504(6):716-729.
32. Glezer I., Simard A.R., Rivest S. Neuroprotective role of the innate immune system by microglia. Neuroscience 2007, 147(4):867-883.
33. Persson M., et al. Lipopolysaccharide increases microglial GLT-1 expression and glutamate uptake capacity in vitro by a mechanism dependent on TNF-alpha. Glia 2005, 51(2):111-120.
34. Shaked I., et al. Protective autoimmunity: interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. J. Neurochem. 2005, 92(5):997-1009.
35. Trapp B.D., et al. Evidence for synaptic stripping by cortical microglia. Glia 2007, 55(4):360-368.
36. Butovsky O., et al. Microglia activated by IL-4 or IFN-gamma differentially induce neurogenesis and oligodendrogenesis from adult stem/progenitor cells. Mol. Cell. Neurosci. 2006, 31(1):149-160.
37. Domercq M., Vazquez-Villoldo N., Matute C. Neurotransmitter signaling in the pathophysiology of microglia. Front. Cell. Neurosci. 2013, 7:49.
38. Erny D., et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat. Neurosci. 2015, 18(7):965-977.
39. Kimelberg H.K., Nedergaard M. Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics 2010, 7(4):338-353.
40. Sofroniew M.V., Vinters H.V. Astrocytes: biology and pathology. Acta Neuropathol. 2010, 119(1):7-35.
41. Clarke L.E., Barres B.A. Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 2013, 14(5):311-321.
42. Tang F., et al. Lactate-mediated glia-neuronal signalling in the mammalian brain. Nat. Commun. 2014, 5:3284.
43. Sofroniew M.V. Astrogliosis. Cold Spring Harb. Perspect. Biol. 2015, 7(2):pa020420.
44. Parpura V., Haydon P.G. Physiological astrocytic calcium levels stimulate glutamate release to modulate adjacent neurons. Proc. Natl. Acad. Sci. USA 2000, 97(15):8629-8634.
45. Singh A.V., et al. Astrocytes increase ATP exocytosis mediated calcium signaling in response to microgroove structures. Sci. Rep. 2015, 5:7847.
46. Sun D., Jakobs T.C. Structural remodeling of astrocytes in the injured CNS. Neuroscientist 2012, 18(6):567-588.
47. Sofroniew M.V. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci. 2009, 32(12):638-647.
48. Hennessy E., Griffin E.W., Cunningham C. Astrocytes are primed by chronic neurodegeneration to produce exaggerated chemokine and cell infiltration responses to acute stimulation with the cytokines IL-1beta and TNF-alpha. J. Neurosci. 2015, 35(22):8411-8422.
49. Zlokovic B.V. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57(2):178-201.
50. Maragakis N.J., Rothstein J.D. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat. Clin. Pract. Neurol. 2006, 2(12):679-689.
51. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7(1):41-53.
52. Kassmann C.M., et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat. Genet. 2007, 39(8):969-976.
53. Sarnat H.B. Ependymal reactions to injury. A review. J. Neuropathol. Exp. Neurol. 1995, 54(1):1-15.
54. Lattke M., et al. Nuclear factor kappaB activation impairs ependymal ciliogenesis and links neuroinflammation to hydrocephalus formation. J. Neurosci. 2012, 32(34):11511-11523.
55. Heppner F.L., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 2005, 11(2):146-152.
56. Gowing G., Vallieres L., Julien J.P. Mouse model for ablation of proliferating microglia in acute CNS injuries. Glia 2006, 53(3):331-337.
57. Biber K., Owens T., Boddeke E. What is microglia neurotoxicity (Not)?. Glia 2014, 62(6):841-854.
58. Frank-Cannon T.C., et al. Does neuroinflammation fan the flame in neurodegenerative diseases?. Mol. Neurodegener. 2009, 4:47.
59. Aschner M., et al. Glial cells in neurotoxicity development. Annu. Rev. Pharmacol. Toxicol. 1999, 39:151-173.
60. Minkiewicz J., de Rivero Vaccari J.P., Keane R.W. Human astrocytes express a novel NLRP2 inflammasome. Glia 2013, 61(7):1113-1121.
61. Maslanik T., et al. The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure. Brain Behav. Immun. 2013, 28:54-62.
62. Walsh J.G., Muruve D.A., Power C. Inflammasomes in the CNS. Nat. Rev. Neurosci. 2014, 15(2):84-97.
63. Saxena S., Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011, 71(1):35-48.
64. Wu D.C., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinsons disease. Proc. Natl. Acad. Sci. USA 2003, 100(10):6145-6150.
65. Gao H.M., Zhou H., Hong J.S. NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends Pharmacol. Sci. 2012, 33(6):295-303.
66. Mrak R.E., Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 2005, 26(3):349-354.
67. Reale M., et al. Peripheral cytokines profile in Parkinsons disease. Brain Behav. Immun. 2009, 23(1):55-63.
68. Heneka M.T., et al. NLRP3 is activated in Alzheimers disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493(7434):674-678.
69. Gordon R., et al. Proteolytic activation of proapoptotic kinase protein kinase C delta by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J. Neuroinflamm. 2012, 9:82.
70. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J. Neuroinflamm. 2008, 5:45.
71. Pott Godoy M.C., et al. Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinsons disease. Brain 2008, 131(Pt. 7):1880-1894.
72. Woodruff T.M., et al. The role of the complement system and the activation fragment C5a in the central nervous system. Neuromol. Med. 2010, 12(2):179-192.
73. Farkas I., et al. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimers disease. J. Immunol. 2003, 170(11):5764-5771.
74. Jacob A., Alexander J.J. Complement and blood-brain barrier integrity. Mol. Immunol. 2014, 61(2):149-152.
75. Bodea L.G., et al. Neurodegeneration by activation of the microglial complement-phagosome pathway. J. Neurosci. 2014, 34(25):8546-8556.
76. Briggs D.T., et al. Astrocyte-specific expression of a soluble form of the murine complement control protein Crry confers demyelination protection in the cuprizone model. Glia 2007, 55(14):1405-1415.
77. Wyss-Coray T., et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimers mice. Proc. Natl. Acad. Sci. USA 2002, 99(16):10837-10842.
78. Mukherjee P., Pasinetti G.M. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimers disease. J. Neuroimmunol. 2000, 105(2):124-130.
79. Mantovani S., et al. Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood. J Neuroimmunol 2014, 276(12):213-218.
80. Halle A., et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol. 2008, 9(8):857-865.
81. Johann S., et al. NLRP3 inflammasome is expressed by astrocytes in the SOD1 mouse model of ALS and in human sporadic ALS patients. Glia 2015, 63(12):2260-2273.
82. Walsh J.G., et al. Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS. Retrovirology 2014, 11:35.
83. Heneka M.T., Golenbock D.T., Latz E. Innate immunity in Alzheimers disease. Nat. Immunol. 2015, 16(3):229-236.
84. Heneka M.T., et al. Neuroinflammation in Alzheimers disease. Lancet Neurol. 2015, 14(4):388-405.
85. Crews L., Masliah E. Molecular mechanisms of neurodegeneration in Alzheimers disease. Hum. Mol. Genet. 2010, 19(R1):R12-R20.
86. Tarasoff-Conway J.M., et al. Clearance systems in the brain-implications for Alzheimer disease. Nat. Rev. Neurol. 2015, 11(8):457-470.
87. Heppner F.L., Ransohoff R.M., Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 2015, 16(6):358-372.
88. Jin S.C., et al. Coding variants in TREM2 increase risk for Alzheimers disease. Hum. Mol. Genet. 2014, 23(21):5838-5846.
89. Guerreiro R., et al. TREM2 variants in Alzheimers disease. N. Engl. J. Med. 2013, 368(2):117-127.
90. Hickman S.E., El Khoury J. TREM2 and the neuroimmunology of Alzheimers disease. Biochem. Pharmacol. 2014, 88(4):495-498.
91. Fonseca M.I., et al. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimers disease. J. Immunol. 2009, 183(2):1375-1383.
92. Schuitemaker A., et al. Microglial activation in Alzheimers disease: an (R)-[(1)(1)C]PK11195 positron emission tomography study. Neurobiol. Aging 2013, 34(1):128-136.
93. Villegas-Llerena C., et al. Microglial genes regulating neuroinflammation in the progression of Alzheimers disease. Curr. Opin. Neurobiol. 2015, 36:74-81.
94. Lambert J.C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimers disease. Nat. Genet. 2013, 45(12):1452-1458.
95. Nathan C., et al. Protection from Alzheimers-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J. Exp. Med. 2005, 202(9):1163-1169.
96. Kummer M.P., et al. Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. Neuron 2011, 71(5):833-844.
97. Miklossy J., et al. Alzheimer disease: curly fibers and tangles in organs other than brain. J. Neuropathol. Exp. Neurol. 1999, 58(8):803-814.
98. Roth A.D., et al. Oligodendrocytes damage in Alzheimers disease: beta amyloid toxicity and inflammation. Biol. Res. 2005, 38(4):381-387.
99. Kobayashi K., et al. Apoptosis of astrocytes with enhanced lysosomal activity and oligodendrocytes in white matter lesions in Alzheimers disease. Neuropathol. Appl. Neurobiol. 2002, 28(3):238-251.
100. Baik S.H., et al. Migration of neutrophils targeting amyloid plaques in Alzheimers disease mouse model. Neurobiol. Aging 2014, 35(6):1286-1292.
101. Zenaro E., et al. Neutrophils promote Alzheimers disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med. 2015, 21(8):880-886.
102. Lauro C., et al. Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death. Neuropsychopharmacology 2010, 35(7):1550-1559.
103. Walker D.G., et al. Decreased expression of CD200 and CD200 receptor in Alzheimers disease: a potential mechanism leading to chronic inflammation. Exp. Neurol. 2009, 215(1):5-19.
104. Yang L.B., et al. Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimers disease. J. Neurosci. 2000, 20(20):7505-7509.
105. von Bohlen und Halbach O., Schober A., Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinsons disease. Prog. Neurobiol. 2004, 73(3):151-177.
106. Dauer W., Przedborski S. Parkinsons disease: mechanisms and models. Neuron 2003, 39(6):889-909.
107. McGeer P.L., et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinsons and Alzheimers disease brains. Neurology 1988, 38(8):1285-1291.
108. Vawter M.P., et al. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinsons disease in ventricular cerebrospinal fluid. Exp. Neurol. 1996, 142(2):313-322.
109. Banati R.B., Daniel S.E., Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinsons disease. Mov. Disord. 1998, 13(2):221-227.
110. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinsons disease. Br. J. Pharmacol. 2007, 150(8):963-976.
111. Hunot S., et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. Proc. Natl. Acad. Sci. USA 1997, 94(14):7531-7536.
112. Mogi M., et al. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain. J. Neural Transm. 2000, 107(3):335-341.
113. Hirsch E.C., Hunot S., Hartmann A. Neuroinflammatory processes in Parkinsons disease. Parkinsonism Relat. Disord. 2005, 11(Suppl. 1):S9-S15.
114. Burguillos M.A., et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 2011, 472(7343):319-324.
115. Hartmann A., et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinsons disease. Proc. Natl. Acad. Sci. USA 2000, 97(6):2875-2880.
116. Hartmann A., et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinsons disease, but pathway inhibition results in neuronal necrosis. J. Neurosci. 2001, 21(7):2247-2255.
117. 11C](R)-PK11195 PET in idiopathic Parkinsons disease. Neurobiol. Dis. 2006, 21(2):404-412.
118. Hunot S., et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. USA 1997, 94(14):7531-7536.
119. Brochard V., et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119(1):182-192.
120. Reynolds A.D., et al. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinsons disease. J. Immunol. 2010, 184(5):2261-2271.
121. Kosloski L.M., et al. Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases. J. Neurochem. 2010, 114(5):1261-1276.
122. Reynolds A.D., et al. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinsons disease. J. Leukoc. Biol. 2007, 82(5):1083-1094.
123. Benner E.J., et al. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinsons disease. Proc. Natl. Acad. Sci. USA 2004, 101(25):9435-9440.
124. Langston J.W., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 1999, 46(4):598-605.
125. Hakansson A., et al. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinsons disease. Am. J. Med. Genet. 2005, 133B(1):88-92.
126. Kruger R., et al. Genetic analysis of immunomodulating factors in sporadic Parkinsons disease. J. Neural Transm. 2000, 107(5):553-562.
127. Nishimura M., et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinsons disease. Neurosci. Lett. 2001, 311(1):1-4.
128. Nishimura M., et al. Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinsons disease. Neurosci. Lett. 2000, 284(12):73-76.
129. Schwarzschild M.A., et al. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinsons disease. Neurology 2003, 61(11 Suppl. 6):S55-S61.
130. Chen H., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 2003, 60(8):1059-1064.
131. Chen H., et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinsons disease. Ann. Neurol. 2005, 58(6):963-967.
132. Wahner A.D., et al. Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease. Neurology 2007, 69(19):1836-1842.
133. Checkoway H., et al. Parkinsons disease risks associated with cigarette smoking, alcohol consumption, and caffeine intake. Am. J. Epidemiol. 2002, 155(8):732-738.
134. Brothers H.M., Marchalant Y., Wenk G.L. Caffeine attenuates lipopolysaccharide-induced neuroinflammation. Neurosci. Lett. 2010, 480(2):97-100.
135. Kurkowska-Jastrzebska I., et al. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 1999, 156(1):50-61.
136. Czlonkowska A., et al. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinsons disease mice model. Neurodegeneration 1996, 5(2):137-143.
137. Gordon R., et al. Protein kinase C delta upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinsons disease. Neurobiol. Dis. 2016, 93:96-114.
138. Lawson L.J., et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990, 39(1):151-170.
139. Kim W.G., et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 2000, 20(16):6309-6316.
140. Nadeau S., Rivest S. Glucocorticoids play a fundamental role in protecting the brain during innate immune response. J. Neurosci. 2003, 23(13):5536-5544.
141. Zigmond M.J., Hastings T.G., Perez R.G. Increased dopamine turnover after partial loss of dopaminergic neurons: compensation or toxicity?. Parkinsonism Relat. Disord. 2002, 8(6):389-393.
142. Loeffler D.A., et al. Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin. Neuropharmacol. 1994, 17(4):370-379.
143. Zeevalk G.D., Bernard L.P., Nicklas W.J. Role of oxidative stress and the glutathione system in loss of dopamine neurons due to impairment of energy metabolism. J. Neurochem. 1998, 70(4):1421-1430.
144. Nakamura K., Wang W., Kang U.J. The role of glutathione in dopaminergic neuronal survival. J. Neurochem. 1997, 69(5):1850-1858.
145. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinsons disease. Neurology 1996, 47(6 Suppl. 3):S161-S170.
146. Ros-Bernal F., et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc. Natl. Acad. Sci. USA 2011, 108(16):6632-6637.
147. Cabral G.A., Griffin-Thomas L. Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr. Metab. Immune Disord. Drug Targets 2008, 8(3):159-172.
148. Rivest S. Cannabinoids in microglia: a new trick for immune surveillance and neuroprotection. Neuron 2006, 49(1):4-8.
149. McCarty M.F. Down-regulation of microglial activation may represent a practical strategy for combating neurodegenerative disorders. Med. Hypotheses 2006, 67(2):251-269.
150. Lee J.K., et al. Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J. Neurosci. 2008, 28(34):8517-8528.
151. Lee E.J., et al. Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J. Immunol. 2010, 185(1):615-623.
152. Zhang W., et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinsons disease. FASEB J. 2005, 19(6):533-542.
153. Wilms H., et al. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinsons disease. FASEB J. 2003, 17(3):500-502.
154. Zhang W., et al. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinsons disease. Neurotox. Res. 2011, 19(1):63-72.
155. Kim Y.S., et al. A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. FASEB J. 2007, 21(1):179-187.
156. Kim Y.S., et al. Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. J. Neurosci. 2005, 25(14):3701-3711.
157. Stefano L., et al. The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor. J. Neurochem. 2009, 110(1):284-294.
158. Lehnardt S., et al. A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. J. Neurosci. 2008, 28(10):2320-2331.
159. Waugh J.L., et al. Regional, cellular, and subcellular localization of RGS10 in rodent brain. J. Comp. Neurol. 2005, 481(3):299-313.
160. Shan S., et al. NEW evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinsons disease. Neurobiol. Aging 2011, 32(3):443-458.
161. Cardona A.E., et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 2006, 9(7):917-924.
162. Min K.J., et al. Gangliosides activate microglia via protein kinase C and NADPH oxidase. Glia 2004, 48(3):197-206.
163. Pyo H., et al. Gangliosides activate cultured rat brain microglia. J. Biol. Chem. 1999, 274(49):34584-34589.
164. Wu X.F., et al. The role of microglia in paraquat-induced dopaminergic neurotoxicity. Antioxid. Redox Signal. 2005, 7(56):654-661.
165. Gao H.M., et al. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinsons disease. J. Neurosci. 2003, 23(4):1228-1236.
166. McCoy M.K., et al. TNF: a key neuroinflammatory mediator of neurotoxicity and neurodegeneration in models of Parkinsons disease. Adv. Exp. Med. Biol. 2011, 691:539-540.
167. Barcia C., et al. IFN-gamma signaling, with the synergistic contribution of TNF-alpha, mediates cell specific microglial and astroglial activation in experimental models of Parkinsons disease. Cell Death Dis. 2011, 2:e142.
168. Block M.L., et al. Nanometer size diesel exhaust particles are selectively toxic to dopaminergic neurons: the role of microglia, phagocytosis, and NADPH oxidase. FASEB J. 2004, 18(13):1618-1620.
169. Zhang W., et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinsons disease model: role of NADPH oxidase. FASEB J. 2004, 18(3):589-591.
170. Gao H.M., et al. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinsons disease. FASEB J. 2003, 17(13):1954-1956.
171. Zhang W., et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 2007, 55(11):1178-1188.
172. Qian L., et al. NADPH oxidase inhibitor DPI is neuroprotective at femtomolar concentrations through inhibition of microglia over-activation. Parkinsonism Relat. Disord. 2007, 13(Suppl. 3):S316-S320.
173. Liberatore G.T., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 1999, 5(12):1403-1409.
174. Ghosh A., et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinsons disease. Proc. Natl. Acad. Sci. USA 2007, 104(47):18754-18759.
175. Ghosh A., et al. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinsons disease. J. Neurosci. 2009, 29(43):13543-13556.
176. Zhang F., et al. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol. Pharmacol. 2010, 78(3):466-477.
177. Hernandez-Romero M.C., et al. Simvastatin prevents the inflammatory process and the dopaminergic degeneration induced by the intranigral injection of lipopolysaccharide. J. Neurochem. 2008, 105(2):445-459.
178. McCoy M.K., et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinsons disease. J. Neurosci. 2006, 26(37):9365-9375.
179. Zhang W., et al. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J. 2005, 19(3):395-397.
180. Wang T., et al. Protective effect of the SOD/catalase mimetic MnTMPyP on inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuronal-glial cultures. J. Neuroimmunol. 2004, 147(12):68-72.
181. Robberecht W., Philips T. The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci. 2013, 14(4):248-264.
182. Renton A.E., Chio A., Traynor B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014, 17(1):17-23.
183. Pratt A.J., et al. Aggregation propensities of superoxide dismutase G93 hotspot mutants mirror ALS clinical phenotypes. Proc. Natl. Acad. Sci. USA 2014, 111(43):E4568-E4576.
184. Philips T., Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011, 10(3):253-263.
185. Butovsky O., et al. Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS. J. Clin. Invest. 2012, 122(9):3063-3087.
186. Lampson L.A., Kushner P.D., Sobel R.A. Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann. Neurol. 1990, 28(3):365-372.
187. Lee J.D., et al. Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neuroinflamm. 2013, 10:119.
188. Crotti A., et al. Mutant huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat. Neurosci. 2014, 17(4):513-521.
189. Silvestroni A., et al. Distinct neuroinflammatory profile in post-mortem human Huntingtons disease. Neuroreport 2009, 20(12):1098-1103.
190. Tai Y.F., et al. Microglial activation in presymptomatic Huntingtons disease gene carriers. Brain 2007, 130(Pt. 7):1759-1766.
191. Andrews T.C., et al. Huntingtons disease progression. PET and clinical observations. Brain 1999, 122(Pt. 12):2353-2363.
192. Pavese N., et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006, 66(11):1638-1643.
193. Bjorkqvist M., et al. The R6/2 transgenic mouse model of Huntingtons disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum. Mol. Genet. 2005, 14(5):565-574.
194. Simmons D.A., et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntingtons disease. Glia 2007, 55(10):1074-1084.
195. Shin J.Y., et al. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J. Cell. Biol. 2005, 171(6):1001-1012.
196. Bradford J., et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J. Biol. Chem. 2010, 285(14):10653-10661.
197. Bradford J., et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc. Natl. Acad. Sci. USA 2009, 106(52):22480-22485.
198. Mantovani S., et al. Motor deficits associated with Huntingtons disease occur in the absence of striatal degeneration in BACHD transgenic mice. Hum. Mol. Genet. 2016, 25(9):1780-1791.
199. Pasqualetti G., Brooks D.J., Edison P. The role of neuroinflammation in dementias. Curr. Neurol. Neurosci. Rep. 2015, 15(4):17.
200. Zhang J. Mapping neuroinflammation in frontotemporal dementia with molecular PET imaging. J. Neuroinflamm. 2015, 12:108.
201. Guerreiro R.J., et al. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013, 70(1):78-84.
202. Borroni B., et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol. Aging 2014, 35(4):934e7-934e10.
203. Baker M., et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature 2006, 442(7105):916-919.
204. Martens L.H., et al. Progranulin deficiency promotes neuroinflammation and neuron loss following toxin-induced injury. J. Clin. Invest. 2012, 122(11):3955-3959.
205. Surendranathan A., Rowe J.B., OBrien J.T. Neuroinflammation in Lewy body dementia. Parkinsonism Relat. Disord. 2015, 21(12):1398-1406.
206. Griffin W.S., et al. Interleukin-1 mediates Alzheimer and Lewy body pathologies. J. Neuroinflamm. 2006, 3:5.
207. Gao H.M., et al. Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinsons disease. Environ. Health Perspect. 2011, 119(6):807-814.
208. Qin L., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55(5):453-462.
209. Schroder K., Zhou R., Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger?. Science 2010, 327(5963):296-300.
210. Tschopp J., Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?. Nat. Rev. Immunol. 2010, 10(3):210-215.
211. Youm Y.H., et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 2013, 18(4):519-532.
212. Zhang D., et al. Neuroprotective effect of protein kinase C delta inhibitor rottlerin in cell culture and animal models of Parkinsons disease. J. Pharmacol. Exp. Ther. 2007, 322(3):913-922.
213. Paris D., et al. The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-beta production and Tau hyperphosphorylation. J. Biol. Chem. 2014, 289(49):33927-33944.
214. Panicker N., et al. Fyn kinase regulates microglial neuroinflammatory responses in cell culture and animal models of Parkinsons disease. J. Neurosci. 2015, 35(27):10058-10077.
215. Harms A.S., et al. Delayed dominant-negative TNF gene therapy halts progressive loss of nigral dopaminergic neurons in a rat model of Parkinsons disease. Mol. Ther. 2011, 19(1):46-52.
216. Barnum C.J., et al. Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro(R)1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. J. Parkinsons Dis. 2014, 4(3):349-360.
217. Koprich J.B., et al. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinsons disease. J. Neuroinflamm. 2008, 5:8.
218. Coll R.C., et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat. Med. 2015, 21(3):248-255.
219. Youm Y.H., et al. The ketone metabolite beta-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat. Med. 2015, 21(3):263-269.
220. Vom Berg J., et al. Inhibition of IL-12/IL-23 signaling reduces Alzheimers disease-like pathology and cognitive decline. Nat. Med. 2012, 18(12):1812-1819.
221. Papatriantafyllou M. Immunotherapy: immunological bullets against Alzheimers disease. Nat. Rev. Drug Discov. 2013, 12(1):24.
222. Woodruff T.M., Nandakumar K.S., Tedesco F. Inhibiting the C5-C5a receptor axis. Mol. Immunol. 2011, 48(14):1631-1642.
223. Stephan A.H., Barres B.A., Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu. Rev. Neurosci. 2012, 35:369-389.
224. Sabbagh M.N., et al. PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2011, 25(3):206-212.
225. Scheperjans F., et al. Gut microbiota are related to Parkinsons disease and clinical phenotype. Mov. Disord. 2015, 30(3):350-358.
226. Keene A.C., Joiner W.J. Neurodegeneration: paying it off with sleep. Curr. Biol. 2015, 25(6):R234-R236.
227. Zhu B., et al. Sleep disturbance induces neuroinflammation and impairment of learning and memory. Neurobiol. Dis. 2012, 48(3):348-355.
228. Wisor J.P., Schmidt M.A., Clegern W.C. Evidence for neuroinflammatory and microglial changes in the cerebral response to sleep loss. Sleep 2011, 34(3):261-272.
229. Louveau A., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015, 523(7560):337-341.